Viz.ai, an Israeli medtech startup that offers AI-powered disease detection and care coordination platform, is Israel’s first new unicorn for the month of April. The company hit the unicorn mark when it raised $100 million in a Series D funding round led by Tiger Global and Insight Partners, which left Viz.ai with a $1.2 billion valuation.
The new unicorns and big investments keep on coming for Israel Startup Nation, so Viz.ai is in good company. But its $1.2 billion valuation is nowhere near the $15 billion valuation that Rapyd, an Israeli fintech startup, hit last month.
Viz.ai, located in San Francisco, Tel Aviv, Portugal and Amsterdam, pioneered the use of AI algorithms and machine learning to increase the speed of diagnosis and care for a variety of acute and emergent diseases across hospitals and health systems. The Viz Platform is a transformative, intelligent care coordination solution that unifies synchronized care collaboration, high fidelity mobile image viewing, automated workflows and improved visibility at decision-making moments.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
Viz.ai’s comprehensive neurovascular and vascular AI platform is clinically proven to save time and improve patient outcomes and access to care and is used in more than 1,000 hospitals in the US and EMEA. Viz.ai’s life science portfolio expands the power of the AI-powered Viz Platform to pharmaceutical and medical device companies who are leaning into digital transformation to bring life-saving therapies to market more efficiently. The company was named to the Forbes 2021 Next Billion-Dollar Startups list of the 25 fastest-growing venture-backed startups and has been on the Forbes AI 50 list for three consecutive years.
“Viz.ai is committed to helping patients get better, faster and more equitable access to life saving treatments,” said Chris Mansi, MD, Viz.ai co-founder and CEO. “We will continue to invest heavily in cutting edge technology and services to integrate deeply into the clinical workflow, allowing us to automate disease detection, increase diagnostic rates and enhance workflows across the entire hub and spoke health system. More patients receive the right treatment, resulting in better patient outcomes and improved financial efficiency for the health system.”